A phase II study of OSI-774 [erlotinib] in elderly subjects with previously untreated advanced non-small cell lung cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Aug 2016 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016.
- 05 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 29 Feb 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.